LitAlert ~~

    • Phylogenetic Analysis IDs Subset of De Novo Tumors Unrelated to Primary DCIS.
    • Ray T.
    • GenomeWeb. Disease Areas. Cancer. 2022 Apr 11.
    • Some Recurrent DCIS Breast Tumors are Actually New Lesions.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Apr 11.
    • An Exposure-Response Model with Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial.
    • Stodtmann S, Eckert D, Joshi R, Nuthalapati S, Ratajczak CK, Menon R, Mensing S, Xiong H.
    • J Clin Pharmacol. 2022 Apr 10. doi: 10.1002/jcph.2061. Epub ahead of print.

    Identifier: NCT02163694: A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer. (

    • Habitat Analysis of Breast Cancer-Enhanced MRI Reflects BRCA1 Mutation Determined by Immunohistochemistry.
    • Du T, Zhao H.
    • Biomed Res Int. 2022 Mar 30;2022:9623173. doi: 10.1155/2022/9623173.
    • Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib.
    • Anzellini D, Arcangeli G, Del Bianco S.
    • Cancer Diagn Progn. 2022 Jan 3;2(1):84-86. doi: 10.21873/cdp.10080.